JP7596298B2 - 免疫応答を調節するためおよび疾患を処置するためのｂｔｌａ結合（ｃｄ２７２）抗体 - Google Patents

免疫応答を調節するためおよび疾患を処置するためのｂｔｌａ結合（ｃｄ２７２）抗体 Download PDF

Info

Publication number
JP7596298B2
JP7596298B2 JP2021560478A JP2021560478A JP7596298B2 JP 7596298 B2 JP7596298 B2 JP 7596298B2 JP 2021560478 A JP2021560478 A JP 2021560478A JP 2021560478 A JP2021560478 A JP 2021560478A JP 7596298 B2 JP7596298 B2 JP 7596298B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
btla
antibody
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021560478A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022528005A (ja
JP2022528005A5 (https=
Inventor
エイ ゼベル，ブライアン
エイ リッピンコット，ジョン
ジェン，ヤーユエ
バマン ラオ，メガ
タン，ミャオ
ピー マイニンガー，デイビッド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trianni Inc
Curia IP Holdings LLC
Original Assignee
Trianni Inc
Curia IP Holdings LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trianni Inc, Curia IP Holdings LLC filed Critical Trianni Inc
Publication of JP2022528005A publication Critical patent/JP2022528005A/ja
Publication of JP2022528005A5 publication Critical patent/JP2022528005A5/ja
Priority to JP2024206358A priority Critical patent/JP2025041629A/ja
Application granted granted Critical
Publication of JP7596298B2 publication Critical patent/JP7596298B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021560478A 2019-04-01 2020-03-31 免疫応答を調節するためおよび疾患を処置するためのｂｔｌａ結合（ｃｄ２７２）抗体 Active JP7596298B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024206358A JP2025041629A (ja) 2019-04-01 2024-11-27 免疫応答を調節するためおよび疾患を処置するためのｂｔｌａ結合（ｃｄ２７２）抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962827744P 2019-04-01 2019-04-01
US62/827,744 2019-04-01
PCT/US2020/025936 WO2020205849A1 (en) 2019-04-01 2020-03-31 Btla-binding (cd272) antibodies for modulating immune response and treating disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024206358A Division JP2025041629A (ja) 2019-04-01 2024-11-27 免疫応答を調節するためおよび疾患を処置するためのｂｔｌａ結合（ｃｄ２７２）抗体

Publications (3)

Publication Number Publication Date
JP2022528005A JP2022528005A (ja) 2022-06-07
JP2022528005A5 JP2022528005A5 (https=) 2023-04-07
JP7596298B2 true JP7596298B2 (ja) 2024-12-09

Family

ID=70296156

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021560478A Active JP7596298B2 (ja) 2019-04-01 2020-03-31 免疫応答を調節するためおよび疾患を処置するためのｂｔｌａ結合（ｃｄ２７２）抗体
JP2024206358A Pending JP2025041629A (ja) 2019-04-01 2024-11-27 免疫応答を調節するためおよび疾患を処置するためのｂｔｌａ結合（ｃｄ２７２）抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024206358A Pending JP2025041629A (ja) 2019-04-01 2024-11-27 免疫応答を調節するためおよび疾患を処置するためのｂｔｌａ結合（ｃｄ２７２）抗体

Country Status (8)

Country Link
US (2) US11384146B2 (https=)
EP (1) EP3946622A1 (https=)
JP (2) JP7596298B2 (https=)
KR (1) KR20220047536A (https=)
CN (2) CN114585416B (https=)
CA (1) CA3135836A1 (https=)
IL (1) IL286838A (https=)
WO (1) WO2020205849A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023546713A (ja) * 2020-10-23 2023-11-07 アナプティスバイオ インコーポレイティッド Ｂ及びｔリンパ球アテニュエータ（ｂｔｌａ）調節因子及びその使用方法
MX2024007054A (es) * 2021-12-10 2024-09-04 Merck Sharp & Dohme Llc Aglutinantes de mesotelina humana.
US20250304693A1 (en) * 2022-01-29 2025-10-02 Hifibio, Inc. Anti-btla antibodies and uses thereof in treating cancer
US20230322929A1 (en) * 2022-04-12 2023-10-12 Shanghai Junshi Biosciences Co., Ltd. Compositions and Methods for Treating Solid Tumors with Anti-BTLA as Mono or Combination Therapy
CN120322455A (zh) * 2022-07-19 2025-07-15 舒泰神(加州)生物科技有限公司 特异性识别b和t淋巴细胞衰减器(btla)的抗体及其应用
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2025250861A1 (en) * 2024-05-31 2025-12-04 Icahn School Of Medicine At Mount Sinai Broadly neutralizing anti-hcmv antibodies and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013500715A (ja) 2009-07-31 2013-01-10 メダレックス インコーポレーティッド Ｂｔｌａに対する完全ヒト抗体
WO2017144668A1 (en) 2016-02-26 2017-08-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity for btla and uses thereof
JP2018521959A (ja) 2015-04-29 2018-08-09 サンフォード−バーナム メディカル リサーチ インスティテュート Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション
JP2019502405A (ja) 2015-12-02 2019-01-31 ストサイエンシス， インコーポレイテッド グリコシル化ｂｔｌａ（ｂ−及びｔ−リンパ球減弱因子）に特異的な抗体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
EP1560593B1 (en) 2002-10-25 2016-04-20 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
AU2004297616B2 (en) 2003-12-04 2008-12-18 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
MY151191A (en) * 2007-09-26 2014-04-30 Genentech Inc Novel antibodies
CA2961439A1 (en) 2014-11-05 2016-05-12 Genentech, Inc. Anti-fgfr2/3 antibodies and methods using same
KR20230119259A (ko) * 2016-04-15 2023-08-16 이뮤넥스트, 인크. 항-인간 vista 항체 및 이의 용도

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013500715A (ja) 2009-07-31 2013-01-10 メダレックス インコーポレーティッド Ｂｔｌａに対する完全ヒト抗体
JP2018521959A (ja) 2015-04-29 2018-08-09 サンフォード−バーナム メディカル リサーチ インスティテュート Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション
JP2019502405A (ja) 2015-12-02 2019-01-31 ストサイエンシス， インコーポレイテッド グリコシル化ｂｔｌａ（ｂ−及びｔ−リンパ球減弱因子）に特異的な抗体
WO2017144668A1 (en) 2016-02-26 2017-08-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity for btla and uses thereof

Also Published As

Publication number Publication date
CN114585416B (zh) 2025-01-17
CN114585416A (zh) 2022-06-03
JP2025041629A (ja) 2025-03-26
JP2022528005A (ja) 2022-06-07
IL286838A (en) 2021-10-31
US20230340123A1 (en) 2023-10-26
WO2020205849A1 (en) 2020-10-08
KR20220047536A (ko) 2022-04-18
US20200325230A1 (en) 2020-10-15
CN119735682A (zh) 2025-04-01
US11384146B2 (en) 2022-07-12
CA3135836A1 (en) 2020-10-08
EP3946622A1 (en) 2022-02-09

Similar Documents

Publication Publication Date Title
JP7596298B2 (ja) 免疫応答を調節するためおよび疾患を処置するためのｂｔｌａ結合（ｃｄ２７２）抗体
US12404327B2 (en) LILRB3-binding molecules and uses therefor
US20240150462A1 (en) Lilrb1 and lilrb2-binding molecules and uses therefor
US20220153834A1 (en) Tsg-6 antibodies and uses therefor
US12286476B2 (en) FCMR-binding molecules and uses thereof
EA046937B1 (ru) Lilrb3-связывающие молекулы и варианты их применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230330

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230330

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20230713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230713

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240305

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240604

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240904

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241029

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241127

R150 Certificate of patent or registration of utility model

Ref document number: 7596298

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150